PriceTargets.com logo

Oxford Biomedica - OXBDF Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.62 As of 04/18/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for OXBDF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oxford Biomedica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OXBDF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OXBDF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for Oxford Biomedica in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.62.

This chart shows the closing price for OXBDF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Oxford Biomedica. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/22/2023JPMorgan Chase & Co.Lower TargetGBX 495 ➝ GBX 325
9/4/2023Liberum CapitalDowngradeBuy ➝ Hold
8/4/2023Stifel NicolausDowngradeBuy ➝ Hold
6/20/2023JPMorgan Chase & Co.Initiated CoverageNeutral
5/3/2023Cantor FitzgeraldInitiated CoverageOverweight
4/25/2023HC WainwrightReiterated RatingBuy
10/11/2022Royal Bank of CanadaBoost TargetGBX 1,020 ➝ GBX 1,110
4/20/2022HC WainwrightReiterated RatingBuy
9/22/2021HC WainwrightReiterated RatingBuy
7/7/2021Panmure GordonUpgradeHold ➝ Buy
6/21/2021Royal Bank of CanadaReiterated RatingOutperform
5/25/2021Royal Bank of CanadaReiterated RatingOutperform
5/14/2021InvestecUpgradeSell ➝ Hold
11/2/2020HC WainwrightReiterated RatingBuy
9/17/2020HC WainwrightReiterated RatingBuy
9/8/2020Royal Bank of CanadaReiterated RatingBuy
9/2/2020HC WainwrightReiterated RatingBuy
8/4/2020HC WainwrightReiterated RatingBuy
7/28/2020Liberum CapitalReiterated RatingBuy
7/28/2020Peel HuntReiterated RatingBuy
7/27/2020Royal Bank of CanadaInitiated CoverageOutperform
5/6/2020HC WainwrightReiterated RatingBuy
12/19/2019HC WainwrightReiterated RatingBuy
9/4/2019HC WainwrightReiterated RatingBuy$14.50
5/28/2019HC WainwrightReiterated RatingBuy$14.50
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Oxford Biomedica logo
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
Read More

Today's Range

Now: $2.62
Low: $2.62
High: $2.62

50 Day Range

MA: $2.43
Low: $2.09
High: $2.72

52 Week Range

Now: $2.62
Low: $2.09
High: $6.02

Volume

N/A

Average Volume

184 shs

Market Capitalization

$251.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Oxford Biomedica?

The following sell-side analysts have issued stock ratings on Oxford Biomedica in the last year: Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co., Liberum Capital, and Stifel Nicolaus.
View the latest analyst ratings for OXBDF.

What is the current price target for Oxford Biomedica?

0 Wall Street analysts have set twelve-month price targets for Oxford Biomedica in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Oxford Biomedica in the next year.
View the latest price targets for OXBDF.

What is the current consensus analyst rating for Oxford Biomedica?

Oxford Biomedica currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OXBDF, but not buy more shares or sell existing shares.
View the latest ratings for OXBDF.

What other companies compete with Oxford Biomedica?

Other companies that are similar to Oxford Biomedica include Semperit Aktiengesellschaft, Adocia, Ascend Wellness, Xeris Biopharma and GeneDx. Learn More about companies similar to Oxford Biomedica.

How do I contact Oxford Biomedica's investor relations team?

Oxford Biomedica's physical mailing address is Windrush Court Transport Way, Oxford X0, OX4 6LT. The company's listed phone number is 44-18-6578-3000 and its investor relations email address is [email protected]. The official website for Oxford Biomedica is www.oxfordbiomedica.co.uk. Learn More about contacing Oxford Biomedica investor relations.